全文获取类型
收费全文 | 5918篇 |
免费 | 455篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 251篇 |
妇产科学 | 133篇 |
基础医学 | 683篇 |
口腔科学 | 86篇 |
临床医学 | 1096篇 |
内科学 | 1017篇 |
皮肤病学 | 75篇 |
神经病学 | 385篇 |
特种医学 | 249篇 |
外科学 | 603篇 |
综合类 | 185篇 |
一般理论 | 4篇 |
预防医学 | 814篇 |
眼科学 | 61篇 |
药学 | 366篇 |
中国医学 | 1篇 |
肿瘤学 | 335篇 |
出版年
2023年 | 27篇 |
2022年 | 43篇 |
2021年 | 116篇 |
2020年 | 74篇 |
2019年 | 116篇 |
2018年 | 133篇 |
2017年 | 107篇 |
2016年 | 122篇 |
2015年 | 129篇 |
2014年 | 163篇 |
2013年 | 333篇 |
2012年 | 453篇 |
2011年 | 417篇 |
2010年 | 250篇 |
2009年 | 209篇 |
2008年 | 405篇 |
2007年 | 404篇 |
2006年 | 405篇 |
2005年 | 408篇 |
2004年 | 393篇 |
2003年 | 380篇 |
2002年 | 377篇 |
2001年 | 62篇 |
2000年 | 64篇 |
1999年 | 71篇 |
1998年 | 73篇 |
1997年 | 47篇 |
1996年 | 45篇 |
1995年 | 42篇 |
1994年 | 27篇 |
1993年 | 22篇 |
1992年 | 33篇 |
1991年 | 23篇 |
1990年 | 29篇 |
1989年 | 29篇 |
1988年 | 19篇 |
1987年 | 16篇 |
1986年 | 13篇 |
1985年 | 22篇 |
1984年 | 24篇 |
1983年 | 26篇 |
1982年 | 17篇 |
1981年 | 25篇 |
1980年 | 12篇 |
1979年 | 14篇 |
1978年 | 18篇 |
1975年 | 12篇 |
1974年 | 12篇 |
1972年 | 21篇 |
1971年 | 16篇 |
排序方式: 共有6399条查询结果,搜索用时 11 毫秒
991.
992.
993.
Platelet-rich plasma (PRP) is a solution derived from whole blood that is enriched in the platelet fraction. Platelets serve as a reservoir of growth factors and cytokines. When platelets are activated in vivo, signaling molecules are released into the immediate microenvironment and activate receptors for various pathways. Historically, PRP has been applied to wound beds to promote healing of complex wounds. Over the last decade, it has served as a valuable therapeutic tool in various specialties such as maxillofacial surgery, plastic surgery, orthopedics and sports medicine. Only recently has PRP been utilized for dermatologic purposes, more specifically, for the treatment of male and female pattern hair loss. In this review, we discuss molecular and cellular pathways upregulated by PRP important in hair folliculogenesis, and examine clinical evidence from all previously published studies involving the use of PRP for pattern hair loss. 相似文献
994.
995.
996.
997.
Clinical and echocardiographic characteristics of patients in sinus rhythm,normal left ventricular function,and indeterminate diastolic function
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
998.
Cindy Lynne Miller 《Women & health》2020,60(7):763-775
ABSTRACT We explored whether the guilt mothers of young children feel about engaging in health behaviors mediates the relationship between self-compassion and self-reported engagement in health-promoting behaviors such as physical activity, eating a healthy diet and getting enough sleep. In this online, cross-sectional study, 143 mothers of young children completed measures of self-compassion, guilt about taking time to engage in health-promoting behaviors, trait guilt, health-promoting behaviors, self-esteem, and demographics. Mediation analysis, using Hayes’ PROCESS macro showed that mother guilt mediated the relationship between self-compassion and health-promoting behaviors, ß = .05, Bca CI (.0014, .1133) with a bootstrapped standard error of .03 and a 95% confidence interval. Self-compassion may offer mothers a positive way to deal with guilty feelings about looking after their health. 相似文献
999.
Sundar Jagannath Rafat Abonour Brian G.M. Durie Cristina Gasparetto James W. Hardin Mohit Narang Howard R. Terebelo Kathleen Toomey Lynne Wagner Shankar Srinivasan Amani Kitali Lihua Yue E.Dawn Flick Amit Agarwal Robert M. Rifkin 《Clinical Lymphoma, Myeloma & Leukemia》2018,18(7):480-485.e3
Background
The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second- and later-line disease. Using data from Connect MM, the largest multisite, primarily community-based, prospective, observational registry of MM patients in the United States, selection of second-line treatments was evaluated during a 5-year period from 2010 to 2016.Patients and Methods
Eligible patients were aged ≥ 18 years, had newly diagnosed MM ≤ 2 months before study entry, and were followed for up to 8 years. Patients who received ≥ 2 lines of therapy were analyzed. “Tepee” plots of stacked area graphs differentiated treatments by color to allow visualization of second-line treatment trends in MM patients.Results
As of February 2017, 855 of 2897 treated patients had progressed to second-line treatment. Treatment selection was heterogeneous; shifting patterns of treatment choices coincided with the approval status of newer agents. The most common treatment regimens in the early part of the decade were lenalidomide and/or bortezomib, with or without dexamethasone, with increasing use of newer agents (carfilzomib, pomalidomide, daratumumab, and elotuzumab) and triplet combinations over time. The influence of the baseline patient characteristics of age, history of diabetes, peripheral neuropathy, and renal function on treatment choice was also examined.Conclusion
These findings indicate that community physicians are current in their MM management practices, with uptake of new drugs and acquaintance with results of randomized clinical trials using combinations almost concurrent with their regulatory approval and publication. 相似文献1000.